Get the latest Science News and Discoveries
Insilico delivers second preclinical candidate compound (PCC) to Fosun Pharma - EurekAlert
Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has successfully delivered the second preclinical candidate compound (PCC) in its collaboration with Fosun Pharma in June 2024, a potential innovative therapeutic using synthetic lethal strategy for the treatment of solid tumors. Insilico expects to submit the pre-IND application for this candidate with the CDE in 2024 Q4.
None
Or read this on Eureka Alert